Summary of the Conference Call on Sanofi Biopharmaceuticals Company Overview - The conference focused on Sanofi Biopharmaceuticals, a well-established biopharmaceutical company with a strong growth trajectory in its core business [1][2] - The company operates primarily in three segments: biopharmaceuticals, chemical drugs, and CDMO (Contract Development and Manufacturing Organization) services [2] Core Business and Products - The main revenue drivers are biopharmaceuticals, particularly the product Tevaz (TPU) and its injectable form EPO, which have significant sales in various medical fields including nephrology, dermatology, autoimmune diseases, and oncology [3] - The company also has a growing OTC (over-the-counter) product line under the brand Mandy, which has shown rapid sales growth in recent years [3] Financial Performance - The company reported double-digit growth in both revenue and profit for the first half of the year, with expectations to maintain this momentum in the second half [4][5] - Tevaz sales reached approximately 2.5 billion RMB in the first half, with projections of around 5 billion RMB for the full year, indicating a strong growth outlook [4] - The company’s valuation is considered low relative to its stable earnings and dividend payouts, making it an attractive investment opportunity [5] Clinical Developments - Sanofi's innovative drug, the PDZ and BGF dual antibody 707, has shown promising early clinical data, particularly in non-small cell lung cancer and colorectal cancer trials [6][7] - The drug has demonstrated an overall response rate (ORR) of 59% in early trials, with a disease control rate (DCR) close to 100% [7] - The company is expected to enter Phase III registration trials in China by the end of the year, indicating a strong clinical development pipeline [8][11] Market Trends and Competitive Landscape - The market is witnessing a shift towards combination therapies involving PD-1 and PD-L1 dual antibodies, with Sanofi's 707 positioned favorably among competitors [10][11] - There is a growing demand for dual antibody therapies, and Sanofi's 707 is seen as having significant potential for external licensing opportunities [11][12] Conclusion - Sanofi Biopharmaceuticals is recognized for its stable core business and innovative product pipeline, particularly the promising 707 dual antibody. The company is positioned for continued growth and is considered a valuable investment opportunity in the biopharmaceutical sector [12]

Summary of the Conference Call for Sanofi Pharmaceutical Company Overview - **Company**: Sanofi Pharmaceutical - **Core Products**: Teibiao and Mandi (Minoxidil) - **Industry**: Pharmaceutical Key Points and Arguments Product Growth Expectations - Teibiao is expected to grow by approximately 20% in 2024, benefiting from a zero-price reduction renewal, with sales projected to reach 5 billion yuan, potentially exceeding 6 billion yuan at peak [2][10] - Mandi brand (Minoxidil) is anticipated to achieve double-digit growth in 2024, with sales expected to exceed 2 billion yuan post-consumer recovery [2][14] Pipeline Developments - The PD-1 VEGF dual antibody project has shown promising early-phase data presented at the JP Morgan conference, with a partnership established with Bai Li Tianheng for combined use, indicating potential for global business development transactions [2][6] - Shengke's long-acting erythropoietin is in the NDA stage, with advancements in the blood oncology field's PD-L1 VEGF dual antibody expected to lead to overseas transactions [2][8] - Sanofi Guojian is focusing on autoimmune diseases, with IL-17 and IL-4 monoclonal antibodies in phase III clinical trials, expected to submit for market approval in 2024 [2][15] Sales Performance and Market Impact - Sales declined in 2023 due to centralized procurement impacts, but a small single-digit growth is expected in 2024 as the company adapts with long-acting erythropoietin development [2][12] - Teibiao's sales reached 4.2 billion yuan in 2023, a 23% year-on-year increase, with a projected 5 billion yuan in 2024 [10][16] Management and Ownership Structure - The company has established a strong position in various fields since its inception in 1993, with Chairman and CEO Mr. Liu Jun controlling 21.85% of the shares [3][7] Investment Valuation - The estimated valuation for 2025 is around seven times earnings, suggesting that the current valuation is low, making it an attractive investment opportunity [3][18] Additional R&D Pipeline - Other key projects include long-acting erythropoietin, IL-1β inhibitors, and various collaborations that are expected to contribute to revenue growth in the coming years [8][9] Market Challenges - The company faces pricing pressures from ongoing centralized procurement policies, which may impact future pricing strategies [12] Conclusion - Sanofi Pharmaceutical is positioned for stable growth with its core products and a robust pipeline, despite facing challenges from market dynamics. The current low valuation presents a potential investment opportunity for stakeholders.

Investment Rating - The investment rating for the company is "Outperform the Market" (maintained) [1][18] Core Views - The company is advancing its innovative drug clinical trials rapidly, maintaining steady growth in performance, and currently has a low valuation with stable dividends. Due to the core product sales growth exceeding expectations, the profit forecast has been raised, with projected net profits for 2024-2026 being 2.017 billion, 2.296 billion, and 2.571 billion yuan respectively, representing year-on-year growth of 30.2%, 13.8%, and 12.0% [2][18]. Summary by Sections Strategic Cooperation - The company has reached a strategic cooperation with Bai Li Tian Heng to jointly promote the combined treatment of 707 and BL-B01D1 for solid tumors in China [2]. Product Development - 707 is a PD-1xVEGF dual antibody developed by the company, with advanced research progress and excellent early clinical data, expected to enter Phase III clinical trials in the second half of this year [2][18]. - The core product, Teibiao, continues to see sales growth and has achieved favorable results in medical insurance negotiations, expected to maintain steady growth in 2025-2026 [2][18]. Clinical Data - 707 has shown good clinical data in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), with over 300 patients enrolled in clinical trials [5][9]. - In a Phase II clinical study for PD-L1 positive NSCLC patients, the overall objective response rate (ORR) was 59%, and the disease control rate (DCR) was 97% [6][9]. Competitive Landscape - Compared to other PD-(L)1/VEGF dual antibodies, 707 is at a relatively advanced stage in clinical development, with only one competitor, AK112, having been approved for market [13][18]. - The combination of dual antibodies and antibody-drug conjugates (ADCs) is expected to become a new generation of tumor immunotherapy, with limited competition in the PD-(L)1 dual antibody space [2][18]. Financial Forecast - The company’s financial projections indicate steady revenue growth, with expected revenues of 9.004 billion, 10.123 billion, and 11.177 billion yuan for 2024-2026, respectively [21].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook based on its core products and innovative pipeline [5][11]. Core Views - The company is a leading domestic biopharmaceutical enterprise with a robust innovation strategy and a diverse product portfolio. It has over 40 marketed products across various therapeutic areas, including nephrology, oncology, autoimmune diseases, ophthalmology, and dermatology. Key products like Tevaz (rhTPO) and the Mandi series are expected to maintain steady growth. The company has a rich pipeline with competitive assets in IL-17 and IL-4R, as well as innovative dual antibodies like PD-1/VEGF, which are progressing well [6][13]. Summary by Sections Market Performance - As of February 14, 2025, the closing price is HKD 6.73, with a market capitalization of HKD 16,122.21 million. The stock has a one-year high of HKD 7.85 and a low of HKD 4.91. The debt-to-asset ratio stands at 29.53% [3]. Financial Forecast - The company is projected to achieve revenues of CNY 89.40 billion, CNY 98.38 billion, and CNY 109.26 billion for 2024-2026, with year-on-year growth rates of 14.4%, 10.0%, and 11.1% respectively. Net profits are expected to be CNY 17.69 billion, CNY 20.22 billion, and CNY 23.04 billion, with growth rates of 14.2%, 14.3%, and 13.9% respectively, resulting in a PE ratio of 8, 7, and 7 times [8][11]. Product Pipeline and Innovation - The company has a diverse pipeline focusing on high-potential products in key therapeutic areas. Notable candidates include: - SSS06 (long-acting rhEPO) with NDA acceptance in July 2024. - SSGJ-608 (IL-17 monoclonal antibody) with NDA acceptance in November 2024, expected approval in 2025-2026. - Several other candidates in Phase III clinical trials, including SSGJ-613 (IL-1β) and SSGJ-611 (IL-4R) [7][30]. Core Product Performance - Tevaz, the company's flagship product, achieved a revenue of approximately CNY 24.8 billion in the first half of 2024, reflecting a year-on-year growth of 22.6%. Other products like Mandi also showed positive sales growth, indicating a strong performance across the product portfolio [40][41]. Strategic Collaborations - The company has established multiple strategic collaborations to enhance its product offerings and market reach. Notable partnerships include collaborations for innovative products like HER2 ADC and FLT3 inhibitors, which are expected to contribute to future revenue growth [32][34][35].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 9.91, representing a potential upside of 58.9% from the current price of HKD 6.24 [2][7][8]. Core Insights - The company has demonstrated strong early clinical data for its PD-1/VEGF dual antibody (707), showing promising efficacy in treating various cancers, particularly non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC) [7][8][9]. - The financial outlook is positive, with projected revenue growth of 12% and net profit growth of 13% for FY25, supported by a robust pipeline and favorable market conditions [7][12][15]. - The company is actively pursuing global licensing opportunities for its innovative therapies, indicating potential for international expansion and revenue diversification [7][9][10]. Financial Summary - **Sales Revenue**: Expected to grow from RMB 7,816 million in FY23 to RMB 9,892 million in FY25, reflecting a CAGR of approximately 12.8% [7][12]. - **Net Profit**: Projected to increase from RMB 1,549 million in FY23 to RMB 2,147 million in FY25, with a notable growth rate of 23.2% in FY24 [7][12]. - **Earnings Per Share (EPS)**: Anticipated to rise from RMB 0.64 in FY23 to RMB 0.89 in FY25 [7][12]. - **Valuation Metrics**: The company is trading at a P/E ratio of 6.6 for FY25, indicating attractive valuation compared to industry peers [7][12]. Clinical Development - The company plans to initiate Phase III clinical trials for its 707 therapy targeting NSCLC and CRC in the near future, which could further validate its market potential [7][8][9]. - Multiple early-stage pipelines are entering clinical phases, including promising candidates for pain management and autoimmune diseases, enhancing the company's growth prospects [7][10][12]. Market Position - The company holds a significant market capitalization of HKD 15,080.8 million and has shown resilience in stock performance, with a 52-week price range of HKD 4.94 to HKD 7.82 [2][4]. - The shareholder structure indicates strong institutional support, with TMF (Cayman) Ltd. holding 23.9% and BlackRock, Inc. holding 5.1% [3].

中 國，上 海 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 的 全 部 或 任 何 部 分 內 容 所 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：1530） 本 公 告 乃 由 本 公 司 自 願 刊 發。概 不 保 證 該 產 品 將 最 終 成 功 商 業 化。本 公 司 股 東 及 潛 在 投 資 者 在 買 賣 本 公 司 股 份 時 務 請 審 慎 行 事。 承董事會命 三生制药 主 席 婁競博士 自願公告 三生制药與映恩生物就HER2 ADC藥物達成合作 三生制药（「本公司」）附屬公司瀋陽三生製藥有限責任公司（「瀋陽三生」）及其附屬 公司與映恩生物科技（上 海）有限公司（「映恩生物」），一 家 專 注 於 為 癌 症 和 自 身 免 疫性疾病患者研發新一代A ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 9.03, representing a potential upside of 48.28% from the current price of HKD 6.09 [1][27]. Core Insights - The company has successfully renewed key products, including Tevaz (特比澳) and HER2 monoclonal antibody, which provides a solid foundation for revenue growth. The company is also accelerating its innovative drug pipeline, with multiple products submitted for market approval [11][16][27]. - Revenue projections for the company are estimated at RMB 87.07 billion, RMB 97.31 billion, and RMB 107.1 billion for the years 2024, 2025, and 2026 respectively, with corresponding EPS of RMB 0.84, RMB 0.98, and RMB 1.10 [11][27]. Financial Performance - For the first half of 2024, the company reported total revenue of RMB 44.02 billion, a year-on-year increase of 16.12%. The pre-tax profit was RMB 14.22 billion, up 19.08%, and net profit reached RMB 10.90 billion, reflecting an 11.15% growth [16][20]. - The sales of Tevaz reached RMB 24.8 billion, marking a 22.6% increase compared to the previous year [16][20]. Research and Development - The company is significantly increasing its R&D investments, with a diverse pipeline of 30 products under development, including 15 antibody products and 6 small molecule drugs. Notable collaborations include the exclusive commercialization rights for certain indications of Crizotinib in mainland China [15][17]. - Innovative products such as SSS06, an erythropoietin product for anemia treatment, and other biologics are expected to drive future growth, with several products anticipated to be approved for market launch between 2025 and 2027 [15][22][26].

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 的 全 部 或 任 何 部 分 內 容 所 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 (2) 更改香港主要營業地點的地址 (1) 註銷庫存股份 公告本節內容由三生制药（「本公司」）自 願 作 出。 茲提述(i)本公司日期為二零二三年五月二十二日之通函及本公司日期為二 零 二 三 年 六 月 二 十 日 之 公 告，內 容 有 關（其 中 包 括）本公司股東（「股 東」）於 本 公司於二零二三年六月二十日舉行的股東週年大會上授予購回本公司股份 （「股 份」）之一般授權（「二零二三年購回授權」）；(ii)本公司日期為二零二四年 三 月 二 十 一 日 有 關 建 議 股 份 購 回 之 公 告；及(iii)本公司日期為二零二四年五 月 二 十 四 日 之 通 函 及 本 公 司 日 期 為 二 零 二 四 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 9.81, representing a potential upside of 54.5% from the current price of HKD 6.35 [4][30]. Core Insights - The company is expected to experience rapid growth in its key product, Tevazo, with projected revenues of RMB 5.11 billion in 2024, accounting for 58% of total revenue. The penetration rate of Tevazo among CTIT patients is anticipated to increase from 29% in 2023 to 35% in 2024 [8][9]. - The company has successfully renewed multiple products in the national medical insurance directory, including Tevazo and HER2 monoclonal antibody, which will help stabilize prices and support steady growth [2][3]. - The company has a robust pipeline with several innovative products entering NDA or Phase III clinical trials, expected to be approved between 2025 and 2027, providing new growth momentum [2][3]. Financial Summary - Revenue is projected to grow by 12.8% in 2024 and 12.2% in 2025, with corresponding revenues of RMB 8.82 billion and RMB 9.89 billion respectively [3][20]. - The net profit attributable to shareholders is expected to increase by 23.7% in 2025, reaching RMB 2.18 billion, with a basic earnings per share of RMB 0.90 [3][20]. - The current market capitalization corresponds to a PE ratio of 6.6 times for 2025, indicating an attractive valuation [2][3]. Pipeline and Product Development - The company is advancing its pipeline with several products, including long-acting EPO and IL-17, which are expected to be submitted for approval in 2025 [2][17]. - The introduction of new products, such as the oral solution of paclitaxel and other late-stage clinical products, is anticipated to become significant growth drivers starting in 2026 [2][17]. - The company is also expanding its product offerings in dermatology and hair loss, with promising products like Winlevi and semaglutide in Phase III clinical trials [16][17]. Market Position and Competitive Advantage - The company has established a strong marketing team and channel advantages in the autoimmune field, which will help capture market share for new autoimmune drugs post-launch [15][17]. - Tevazo is positioned as a leading treatment option for chemotherapy-induced thrombocytopenia (CIT), with evidence supporting its efficacy over competitors [10][13].

Investment Rating - The report maintains a "Buy" rating with a target price of HKD 9.81 [4] Core Insights - The company has successfully renewed multiple products in the 2024 National Medical Insurance Directory, including Tevizo and HER2 monoclonal antibody, and has added a new indication for Tevizo in pediatric ITP [1][2] - The company is expected to see stable pricing for renewed products due to ongoing support from the medical insurance fund for innovative drugs, which will contribute to steady growth [1][2] - The company’s revenue is projected to grow by 12.8% in 2024 and 12.2% in 2025, with a corresponding net profit growth of 13.6% in 2025 [4] Summary by Sections - **Product Renewals and New Additions**: Tevizo and HER2 monoclonal antibody have been successfully renewed, with Tevizo gaining a new indication for pediatric ITP. The newly approved drug, sodium naftifine oral disintegrating tablet, has also entered the medical insurance directory [1][2] - **Pipeline Development**: The company is advancing its pipeline with several innovative products entering NDA or Phase III clinical trials, expected to be approved between 2025E and 2027E, providing new growth momentum [1][3] - **Sales and Market Expansion**: The company has established a robust sales capability across various channels, including blood, oncology, nephrology, and rheumatology, and is continuously enriching its innovative pipeline [3] - **Valuation Metrics**: The current market capitalization corresponds to 6.6 times the estimated PE for 2025, indicating an attractive valuation. The expected dividend payout ratio is 30%, with a projected dividend yield of 4.5% for 2025 [1][4]